We are looking to appoint a postdoctoral scientist to join the research group led by Kaan Boztug at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences.
The focus of the group is to understand the molecular mechanisms governing the human immune system by discovering disease-causing gene mutations and studying the resulting pathomechanisms. Ultimately, understanding the immune response at the molecular level will lead to better treatment options (for some recent publications see e.g. Salzer E et al JACI 2014, Boztug K et al Nature Genet 2014, Willmann K et al Nature Communications 2014).
Inherited defects of the human immune system (so-termed “primary immunodeficiencies”, PIDs) represent unique models to dissect essential components of the immune system in natura. A considerable number of PIDs, as well as many other human diseases are characterized by autoimmunity or autoinflammation. However, the molecular mechanisms are often poorly understood. Using NGS-based methods, we have recently identified a number of novel PID candidate genes. The project aims at studying in detail the role of the identified genes in the underlying disease mechanisms by a variety of biochemical, immunological and imaging technologies to obtain molecular gene-to-phenotype relationships. Functional proteomics will be used to mine, uncover and pathway-map gene defects underlying inherited disorders of the immune system with predominant autoimmunity/autoinflammation.
The Lab Infrastructure
A fully equipped molecular biology laboratory in a shared environment with cell culture and multi-color flow cytometry on the same floor within a brand new building. All equipment needed for state-of-the art genomic investigations such as SNP arrays and deep sequencing are immediately accessible on the same floor of the building. The group is embedded in a multidisciplinary and highly collaborative systems biology/molecular medicine research environment providing access to state-of-the-art mass spectrometry, bioinformatics, automated chemical biological screening platform and animal facilities, including BSL2 suites.